Guggenheim took its Sage Therapeutics Inc. [NASDAQ:SAGE] rating to the equivalent of Buy from Neutral, in a research note dated January 4, 2021. Other analysts
Evercore ISI took its Zimmer Biomet Holdings Inc. [ZBH] rating to the equivalent of an Outperform from an In-line, and the price target to $175,
Pivotal Research Group took its Under Armour Inc. [UAA] rating to the equivalent of a Buy from a Hold, and the price target to $20
Jefferies took its Molson Coors Beverage Company [TAP] rating to the equivalent of a Buy from a Hold, and the price target to $57 from
Jefferies took its Newell Brands Inc. [NWL] rating to the equivalent of a Buy from a Hold, and the price target to $28 from $18,
Raymond James took its AT&T Inc. [NYSE:T] rating to the equivalent of Outperform from Market Perform, and the price target to $32, in a research
Barclays took its The Goldman Sachs Group Inc. [NYSE:GS] rating to the equivalent of Overweight from Equal Weight, and the price target to $362, in
Barclays took its Ally Financial Inc. [NYSE:ALLY] rating to the equivalent of Overweight from Equal Weight, and the price target to $48, in a research
Credit Suisse took its Atkore International Group Inc. [NYSE:ATKR] rating to the equivalent of Outperform from Neutral, and the price target to $54, in a
JP Morgan took its The Hartford Financial Services Group Inc. [NYSE:HIG] rating to the equivalent of Overweight from Neutral, and the price target to $55
Jefferies took its Installed Building Products Inc. [NYSE:IBP] rating to the equivalent of Buy from Hold, and the price target to $132 from $106, in
RBC Capital took its Humana Inc. [NYSE:HUM] rating to the equivalent of Outperform from Sector Perform, and the price target to $479 from $429, in
Baird took its Henry Schein Inc. [NASDAQ:HSIC] rating to the equivalent of Outperform from Neutral, and the price target to $79 from $70, in a
BTIG maintained its Palo Alto Networks Inc. [NYSE:PANW] rating to the equivalent of Buy but changed the price target to $419 from $370, in a
BTIG maintained its CrowdStrike Holdings Inc. [NASDAQ:CRWD] rating to the equivalent of Buy but changed the price target to $236 from $206, in a research
H.C. Wainwright maintained its Protalix BioTherapeutics Inc. [AMEX:PLX] rating to the equivalent of Buy but changed the price target to $11, in a research note
Morgan Stanley maintained its Constellation Brands Inc. [NYSE:STZ] rating to the equivalent of Overweight but changed the price target to $240, in a research note
Credit Suisse maintained its Chart Industries Inc. [NASDAQ:GTLS] rating to the equivalent of Outperform but changed the price target to $128 from $109, in a
Credit Suisse maintained its Brown & Brown Inc. [NYSE:BRO] rating to the equivalent of Neutral but changed the price target to $50 from $47, in
Masterlink Securities launched its Shopify Inc. [NYSE:SHOP] rating to the equivalent of Buy, in a research note dated December 31, 2020. Some new analysts also
Masterlink Securities launched its Tesla Inc. [NASDAQ:TSLA] rating to the equivalent of Buy and assigned the price target of $750, in a research note dated
Industrial Securities launched its NetEase Inc. [NASDAQ:NTES] rating to the equivalent of Outperform, in a research note dated December 31, 2020. Some new analysts also
First Shanghai Securities took its Weibo Corporation [NASDAQ:WB] rating to the equivalent of Hold from Buy, and the price target to $44.65, in a research
Shares of Nano Dimension (NNDM) jumped 11.18 % to settle at $9.55. NNDM stock traded 30.84% away from the simple moving average of 20 days.
Argus maintained its FedEx Corporation [NYSE:FDX] rating to the equivalent of Buy but changed the price target to $305 from $270, in a research note
Guggenheim maintained its NIKE Inc. [NYSE:NKE] rating to the equivalent of Buy with a price target $165, in a research note dated December 30, 2020.
Argus took its Vornado Realty Trust [NYSE:VNO] rating to the equivalent of Buy from Hold, and the price target to $42, in a research note
JMP Securities maintained its Ocular Therapeutix Inc. [NASDAQ:OCUL] rating to the equivalent of Outperform but changed the price target to $30 from $20, in a
AstraZeneca PLC (AZN) shares are in green in the pre-market session Wednesday after a British doctor involved in the approval of Oxford/AstraZeneca’s COVID-19 vaccine said
JMP Securities maintained its Evelo Biosciences Inc. [NASDAQ:EVLO] rating to the equivalent of Outperform but changed the price target to $27, in a research note
TF International launched its Fangdd Network Group Ltd. [NASDAQ:DUO] rating to the equivalent of Buy and assigned the price target of $18.91, in a research
Daiwa launched its Vertex Pharmaceuticals Incorporated [NASDAQ:VRTX] rating to the equivalent of Outperform and assigned the price target of $250, in a research note dated
Baird maintained its Welbilt Inc. [NYSE:WBT] rating to the equivalent of Outperform but changed the price target to $17 from $9, in a research note
AlphaValue took its AstraZeneca PLC [NASDAQ:AZN] rating to the equivalent of Add from Reduce, in a research note dated December 30, 2020. Other analysts also
Baird maintained its Caterpillar Inc. [NYSE:CAT] rating to the equivalent of Outperform but changed the price target to $220 from $206, in a research note
Bionano Genomics, Inc. (Nasdaq: BNGO), shares surged 30.08% to $1.73 in the late hours trading session after on December 28, 2020, Bionano Genomics, Inc. (Nasdaq:
KeyBanc took its Continental Resources Inc. [CLR] rating to the equivalent of Overweight from Sector Weight, and the price target to $20, in a research
Goldman Sachs maintained its Veeco Instruments Inc. [NASDAQ:VECO] rating to the equivalent of Buy but changed the price target to $18 from $16, in a
Goldman Sachs maintained its Cree Inc. [NASDAQ:CREE] rating to the equivalent of Neutral but changed the price target to $77 from $67, in a research
Goldman maintained its Snap Inc. [NYSE:SNAP] rating to the equivalent of Buy but changed the price target to $70 from $47, in a research note
Daiwa launched its Amgen Inc. [NASDAQ:AMGN] rating to the equivalent of Buy and assigned the price target of $300, in a research note dated December
Barclays took its Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) rating to the equivalent of Equal Weight from Overweight, and the price target to $46, in
H.C. Wainwright took its Ocular Therapeutix Inc. [OCUL] rating to the equivalent of Neutral from Buy, in a research note dated December 28, 2020. Some
H.C. Wainwright took its SCYNEXIS Inc. [SCYX] rating to the equivalent of a Buy, and the price target to $20 from $35, in a research
H.C. Wainwright maintained its Arcadia Biosciences Inc. [RKDA] rating to the equivalent of a Buy but changed the price target to $8 from $10, in
Morgan Stanley launched its PAE Incorporated [PAE] rating to the equivalent of an Overweight and assigned the price target of $11, in a research note
Get your daily dose of news with exclusive content, articles, and more at The Market Globalist, a free online newspaper launched in May 2010. They’re young, but ambitious, aiming to deliver engaging and informative content. Contribute your own stories and photos to be part of the community!
Copyright © 2024 Market Globalist , All rights reserved.